arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

KALA BIO, Inc.

KALA
$0.56 ▼ -0.03 (-5.10%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
30
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, KALA BIO, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and Interest Coverage. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -442.2% ↘
FCF / Share $-196.31 ↗
Trailing P/E —
Price / Book 0.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-26.98M
↑ +29.9% —
FCF / Share Free cash flow per share
$-196.31
↑ +49.3% —
Long-Term Debt Long-term obligations
$29.28M
↓ -14.3% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -442.2% is weak on an absolute basis (target > 10%)
  • Interest CoverageInterest Coverage of -14.50x is weak on an absolute basis (target > 5x)

Health Breakdown

Financial Health ↑
18
Cash Quality ↑
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 43 quarters